Recent data showing sustained, long-term safety and efficacy of mavrilimumab for the treatment of rheumatoid arthritis (RA) confirm and build on prior evidence from phase 2 studies of the potential for this new agent for the treatment of RA.
Explore this issueNovember 2018
Also by this Author
Mavrilimumab is a human monoclonal antibody that blocks a proinflammatory cytokine involved in RA pathogenesis—granulocyte-macrophage colony-stimulating factor (GM-CSF)—and is the first agent targeting the receptor of this cytokine.
The study found mavrilimumab remained well tolerated with only mild or moderate adverse events and no signs of pulmonary deterioration. In addition, long-term efficacy was maintained.1